TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.95
−1.71%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 8.35x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.63x
- Price / sales
- —
- Price / cash flow
- -40.47x
Enterprise value
- Enterprise value
- $1.8B
- EV / sales
- —
- EV / EBITDA
- -35.47x
- EV / EBIT
- -30.42x
- Market cap
- $2.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026